FINNADVANCE PART OF FINLAND’S EFFORTS ON NANOBIOTECHNOLOGY DERIVED THERAPEUTICS
February 29, 2020
Finnadvance has joined a new research consortium of Finnish pharmaceutical technology and academic research organisations to develop new organ-on-chip platforms for treatment and early diagnostics of central nervous system degenerative diseases and cancer. The consortium’s research will leverage blood-derived extracellular vesicles for potential drug delivery vehicles and biomarkers.
The consortium is formed of 13 partners, including Finland’s leading research organisations, the Finnish Red Cross Blood Service, Orion Pharma, University of Helsinki, University of Eastern Finland, Tampere University, VTT Oulu, UPM Biomedicals, the Biobank of Eastern Finland and innovative SMEs, Kaivogen, Timegate Instruments, Bionavis and Afekta.
The 3 year project (EVE – EV Ecosystem for Theranostic Platforms) is funded by Business Finland and headed by Dr. Saara Laitinen, R&D Manager at Finnish Red Cross Blood Service.
For more information on EVE, please contact:
Saara Laitinen, R&D Manager, Finnish Red Cross Blood Service, tel. +358 29 300 1695 saara.laitinen(at)veripalvelu.fi